Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Saturday, June 29, 2019

Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
Abstract Purpose There is limited evidence on the efficacy and safety of anti-programmed cell death protein 1 (PD-1)-/anti-programmed death-ligand 1 (PD-L1)-based immunotherapy in the elderly, particularly those aged over 75 years. Methods/patients The clinical response and toxicity profile of anti-PD-1-/anti-PD-L1-based immunotherapy in patients aged over...
Clinical and translational oncology
4m
Breast cancer and cytomegalovirus
Abstract Purpose To determine whether cytomegalovirus is causally associated with breast cancer and whether cytomegalovirus should be categorised as an oncogenic virus. Methods We undertook a review of published epidemiological and laboratory studies, using established causal criteria: Bradford Hill criteria to determine whether cytomegalovirus is associated...
Clinical and translational oncology
4m
Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy
Abstract Radiation acts not only through cell death but has also angiogenic, immunomodulatory and bystander effects. The realization of its systemic implications has led to extensive research on the combination of radiotherapy with systemic treatments, including immunotherapy and antiangiogenic agents. Parameters such as dose, fractionation and sequencing of treatments are key determinants of the outcome. However, recent high-quality research indicates that these are not the only...
Clinical and translational oncology
16h
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
Abstract Purpose Immunotherapy is a new standard first-line treatment for non-small cell lung cancers (NSCLC) with high programmed cell death-ligand 1 (PD-L1) expression (≥ 50%) and second-line treatment regardless of PD-L1 status, though not all patients benefit from this approach. Much effort is ongoing to identify robust prognostic and predictive biomarkers of response to immune checkpoint inhibitors, overcoming PD-L1 that appears limited...
Clinical and translational oncology
16h

No comments:

Post a Comment